Results 171 to 180 of about 81,297 (236)

Pharmacologic Modulation of the PAR-2-ERK Axis by Statins Converts Inflammatory Survival Signalling into Apoptosis in Colorectal Cancer Cells. [PDF]

Int J Mol Sci
Amiri L, Patnaik R, Varghese RL, Huda B, Banerjee Y.   +4 more
europepmc   +1 more source

Retrieval Augmented Generation (RAG) for Evaluating Regulatory Compliance of Drug Information and Clinical Trial Protocols

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.
ABSTRACT The purpose was to evaluate retrieval‐augmented generative (RAG) artificial intelligence (AI) methods for assessing the regulatory compliance of drug information and adherence to best practices in clinical trial protocols. Integrated systems containing RAG and large language model (LLM) components were employed to evaluate drug information and
Shreyas Waikar, Amruta Gajanan Bhat, Murali Ramanathan   +2 more
wiley   +1 more source

Atorvastatin suppresses high-risk colorectal adenomas via reprogramming of lipid metabolism and Inhibition of stemness. [PDF]

Sci Rep
Chen W, Ge M, Sun S, Zhang H, Wang Z, Guo Y, Luo Z.   +6 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Targeting HIF-2α in colorectal cancer reveals a cholesterol biosynthesis-dependent ferroptotic vulnerability. [PDF]

Cancer Metab
Dalal PJ, Singhal R, Hu B, Stark D, Rossiter NJ, Jain C, Sajjakulnukit P, Lyssiotis CA, Shah YM.   +8 more
europepmc   +1 more source

Minor Contribution of UGT1A1 Inhibition to Atazanavir‐Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 583-586, March 2026.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source

Managing High‐Risk Drug Interactions With Nirmatrelvir/Ritonavir: Experience From a Dedicated Pharmacology Advice Service

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT Nirmatrelvir boosted with ritonavir is a key antiviral against COVID‐19, yet ritonavir's potent CYP3A4 inhibition exposes patients to numerous drug–drug interactions. To make prescribing safer, a national proactive system providing expert pharmacology advice was implemented in France.
Youssef Libiad, Bénédicte Franck, Camille Tron, Sébastien Lalanne, Christelle Boglione‐Kerrien, Fabrice Taïeb, Marie‐Clémence Verdier, Florian Lemaitre   +7 more
wiley   +1 more source

Statin-Induced Hyper-Acute Reversible Liver Failure: A Case Report. [PDF]

Cureus
AlTurki AA, AlQahtani K, Alnasser AA, AlTalha MM, AlHamdan AS.   +4 more
europepmc   +1 more source

Efficacy and safety of CT‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1673-1682, March 2026.
Abstract Aims To assess the glycaemic efficacy and safety of CT‐868, a cAMP signal‐biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in participants with type 2 diabetes (T2D). Materials and Methods This 26‐week (W), phase 2, randomized, double‐blind placebo‐controlled trial enrolled adults with T2D ...
Manu V. Chakravarthy, Michael A. Elliott, Luis Acosta, Gabriele E. Sonnenberg, Damian Bialonczyk, Jingtao Wu, Federico A. Argüelles‐Tello, Raymundo Garcia‐Reza, José Gerardo González‐González, Stig K. Hansen, Juan P. Frias   +10 more
wiley   +1 more source

The effect of atorvastatin combined with azithromycin on lung function and right heart function in COPD patients with concomitant pulmonary hypertension. [PDF]

Front Med (Lausanne)
Que W, Li S, Li J, Li Y, Ma Z.
europepmc   +1 more source